Processa Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Mar 20, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 20, 2025

PCSA$1.87-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

Years Ended December 31, 2023 and 2024

	Additional
Common Stock · Paid-In · Treasury Stock · Accumulated
	Shares	Amount	Capital	Shares	Amount	Deficit	Total
Balance, January 1, 2023	806,774	80	72,018,222	(5,000)	(300,000)	(64,247,561)	7,470,741
Stock-based compensation	6,945	1	1,060,338	-	-	-	1,060,339
Shares issued in connection with capital raises, net of transaction costs	421,611	42	6,352,035	-	-	-	6,352,077
Warrant granted in connection with a consulting agreement	-	-	1,310,875	-	-	-	1,310,875
Settlement of stock award	-	-	(52,746)	-	-	-	(52,746)
Other	55,670	6	(30,613)	-	-	-	(30,607)
Net loss	-	-	-	-	-	(11,121,520)	(11,121,520)
Balance, December 31, 2023	1,291,000	129	80,658,111	(5,000)	(300,000)	(75,369,081)	4,989,159
Stock-based compensation	62,502	6	629,508	-	-	-	629,514
Shares issued in connection with capital raises, net of transaction costs	2,356,549	236	7,762,843	-	-	-	7,763,079
Shares issued in connection with license agreement	5,000	1	188,999	-	-	-	189,000
Settlement of stock award	-	-	(8,561)	-	-	-	(8,561)
Shares withheld to pay income taxes on stock-based compensation	(7,423)	(1)	(15,901)	-	-	-	(15,902)
Net loss	-	-	-	-	-	(11,850,118)	(11,850,118)
Balance, December 31, 2024	3,707,628	$371	$89,214,999	(5,000)	$(300,000)	$(87,219,199)	$1,696,171

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.